急性髓系白血病与免疫系统:免疫治疗的意义
本文综述了急性髓系白血病(AML)的免疫生物学特征及新型免疫治疗策略。文章总结了AML免疫失调的独特方面,并描述了针对AML免疫抑制和免疫逃逸的重组抗体、过继细胞治疗和疫苗等免疫治疗进展及其未来前景。
要点
- AML存在独特的免疫失调机制,设计免疫治疗需考虑其特殊性。
- 重组抗体、过继细胞治疗和疫苗是AML免疫治疗的重要方向。
- 移植物抗白血病效应显示出免疫治疗治愈AML的潜力。
核心结论
- AML免疫生物学具有独特性,合理设计免疫治疗需考虑其免疫失调和免疫逃逸机制。
- 重组抗体、过继细胞治疗和疫苗等新型免疫治疗在AML治疗中展现出前景。
研究设计与样本
- 本文为综述,总结了当前AML免疫生物学知识及新型免疫治疗进展。
主要发现
- AML存在免疫失调和免疫逃逸,是免疫治疗需克服的关键障碍。
- 重组抗体、过继细胞治疗和疫苗等免疫治疗策略在AML中已有进展。
临床怎么用
- 临床可关注针对AML免疫抑制和免疫逃逸的免疫治疗策略,如重组抗体、过继细胞治疗和疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recognition of the curative potential of the graft-versus-leukaemia effect for patients with acute myeloid leukaemia (AML) undergoing stem cell transplantation, and the emergence of immunotherapy as a powerful weapon to treat cancer, has spurred the exploration of the immune landscape of AML to apply immunotherapeutic approaches to curing the disease. While current concepts of cancer immunology and immunotherapy have relevance, there are also unique aspects of immune dysregulation in AML to be considered when designing rational immunotherapy for this leukaemia. This is timely because rapid advances in cancer immunobiology, together with technological developments have opened up the field of immunotherapy for malignant disease. Here the current knowledge of AML immunobiology is summarized together with a description of new immunotherapies to counter immunosuppression and immune evasion by AML. Recent advances in treatment with recombinant antibodies, adoptive cell therapy and vaccines and their future promise in AML treatment are reviewed.
引用
- Barrett AJ. Acute myeloid leukaemia and the immune system: implications for immunotherapy. Br J Haematol. 2019. PMID: 31782805. doi:10.1111/bjh.16310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。